MIRA INFORM REPORT

 

 

Report Date :

18.01.2013

 

IDENTIFICATION DETAILS

 

Name :

N.K.P. PHARMA PRIVATE LIMITED

 

 

Registered Office :

Plot No. 1814/B, Phase-III,  GIDC, Vatva, Ahmedabad - 382445, Gujarat

 

 

Country :

India

 

 

Financials (as on) :

31.03.2012

 

 

Date of Incorporation :

08.10.2008

 

 

Com. Reg. No.:

04-055212

 

 

Capital Investment / Paid-up Capital :

Rs. 3.000 Millions

 

 

CIN No.:

[Company Identification No.]

U01403GJ2008PTC055212

 

 

Legal Form :

Private Limited Liability Company

 

 

Line of Business :

Manufacturer of Pharmaceutical Machineries.

 

 

No. of Employees :

Not Available

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba (45)

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit :

USD 130000

 

 

Status :

Satisfactory

 

 

Payment Behaviour :

Usually correct

 

 

Litigation :

Clear

 

 

Comments :

Subject is an established company having satisfactory track record. There appears some minimal dip in the profitability. However, networth of the company is satisfactory. Trade relations are reported as fair. Business is active. Payments are reported to be usually correct and as per commitment.

 

The company can be considered normal for business at usual trade terms and condition.

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – June 30, 2012

 

Country Name

Previous Rating

(31.03.2012)

Current Rating

(30.06.2012)

India

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

INDIAN ECONOMIC OVERVIEW

 

India is developing into an open-market economy, yet traces of its past autarkic policies remain. Economic liberalization, including industrial deregulation, privatization of state-owned enterprises, and reduced controls on foreign trade and investment, began in the early 1990s and has served to accelerate the country's growth, which has averaged more than 7% per year since 1997. India's diverse economy encompasses traditional village farming, modern agriculture, handicrafts, a wide range of modern industries, and a multitude of services. Slightly more than half of the work force is in agriculture, but services are the major source of economic growth, accounting for more than half of India's output, with only one-third of its labor force. India has capitalized on its large educated English-speaking population to become a major exporter of information technology services and software workers. In 2010, the Indian economy rebounded robustly from the global financial crisis - in large part because of strong domestic demand - and growth exceeded 8% year-on-year in real terms. However, India's economic growth in 2011 slowed because of persistently high inflation and interest rates and little progress on economic reforms. High international crude prices have exacerbated the government's fuel subsidy expenditures contributing to a higher fiscal deficit, and a worsening current account deficit. Little economic reform took place in 2011 largely due to corruption scandals that have slowed legislative work. India's medium-term growth outlook is positive due to a young population and corresponding low dependency ratio, healthy savings and investment rates, and increasing integration into the global economy. India has many long-term challenges that it has not yet fully addressed, including widespread poverty, inadequate physical and social infrastructure, limited non-agricultural employment opportunities, scarce access to quality basic and higher education, and accommodating rural-to-urban migration.

Source : CIA

 

RBI DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

 

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2012.

 

LOCATIONS

 

Registered Office :

Plot No. 1814/B, Phase-III,  GIDC, Vatva, Ahmedabad - 382445, Gujarat, India

Tel. No.:

91-79-25890834 / 25891746

Fax No.:

91-79-25894282

E-Mail :

mnshahco@gmail.com

info@nkppharma.com

response@pharmamachineriesindia.com

Website :

http://www.pharmamachineriesindia.com

http://www.nkppharma.com

 

 

DIRECTORS

 

As on 30.08.2012

 

Name :

Mr. Darshan Natvarlal Mevada

Designation :

Director

Address :

S/O, Natwarlal Mevada, 40/B Uganda Park Society, Bahiravnath Road, Maninagar, Ahmedabad- 380008, Gujarat, India

Date of Birth/Age :

17.04.1977

Date of Appointment :

08.10.2008

DIN No.:

01818221

 

 

Name :

Mr. Hitesh Natvarlal Mevada

Designation :

Director

Address :

S/O, Natwarlal Mevada, 40/B Uganda Park Society, Bahiravnath Road, Maninagar, Ahmedabad- 380008, Gujarat, India

Date of Birth/Age :

04.08.1975

Date of Appointment :

08.10.2008

DIN No.:

01820149

 

 

 

MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN

 

As on 30.08.2012

 

Names of Shareholders (Preference Share)

 

No. of Shares

Darshan H Mevada (HUF)

 

15000

Hitesh N Mevada (HUF)

 

15000

Payal H Mevada

 

10000

Mittal H Mevada

 

10000

Natverlal R Mevada (HUF)

 

75000

Rukhiben N Mevada

 

75000

Total

 

200000

 

 

As on 30.08.2012

 

Names of Shareholders (Equity Share)

 

No. of Shares

Hitesh N Mevada

 

4500

Darshan N Mevada

 

4500

Mittal H Mevada

 

20000

Payal D Mevada

 

20000

Natverlal R Mevada (HUF)

 

500

Rukhiben N. Mevada

 

9500

Darshan H Mevada (HUF)

 

8000

Hitesh N Mevada (HUF)

 

8000

Teeshan D Mevada

 

6250

Prem D Mevada

 

6250

Maan H Mevada

 

12500

Total

 

100000

 

 

As on 30.08.2012

Equity Share Break up (Percentage of Total Equity)

 

Category

Percentage

Bodies corporate

83.50

Directors or relatives of Directors

16.50

Total

100.00

 

 

BUSINESS DETAILS

 

Line of Business :

Manufacturer of Pharmaceutical Machineries.

 

 

Products :

·         Washing and Cleaning

·         Filling

·         Sealing

·         Ext. Washing and Drying

·         Inspection

·         Sticker Labeling

·         Accessories

 

 

GENERAL INFORMATION

 

Customers :

·         Aristo Pharmaceuticals Private Limited

·         Aristo Laboratories Private Limited

·         Biochem Lab Limited

·         Cadila Healthcare Limited.

·         Cadila Pharmaceuticals Limited

·         Contacare Ophthalmics Limited

·         Biotech Ophthalmics Private Limited

·         Diamond Biolife Private Limited

·         Elysium Pharma Private Limited

·         Emcure Limited

·         Haffkine Bio-pharma Private Limited

·         Hindustan Antibiotics Private Limited

·         Intas Pharma Limited

·         Kilitch Drugs Limited

·         Astral Pharmaceuticals Limited

·         Nirma Limited (Nirlife Healthcare)

·         Serum Institute of India Limited

·         Sun Pharmaceutical Industries Limited

·         Unimed Technologies Limited

·         Bharat Biotech Limited

·         Brilliant Biosciences Limited

·         Nectar laboratories Limited

·         Dano Vaccines Private Limited

·         Shantha Biotech Limited

·         Celon Life Sciences Limited

 

 

No. of Employees :

Not Available

 

 

Bankers :

·         Axis Bank Limited, Ground Floor, Business Square Building, Near Krishna Baug Char Rasta , Maninagar, Ahmedabad - 380008, Gujarat, India

·         The Kukarwada Nagrik Sahakari Bank Limited, Krishna Complex, Hathipura, Madhupura, Ahmedabad - 380004, Gujarat, India

 

 

Facilities :

(Rs. In Millions)

Secured Loan

As on

31.03.2012

As on

31.03.2011

Long Term Borrowings

 

 

Term loan :

 

 

Tata Capital Limited

0.000

0.075

HDFC Bank Limited

(Secured By Vehicle)

Terms of Repayment 36 Months

1.018

0.000

Loan Repayable on Demand

From Banks

 

 

Cash Credit A\c

(secured by Inventory)

21.270

19.568

F.D. O.D. with Bank of Baroda

0.002

0.000

Total

22.290

19.643

 

 

 

Banking Relations :

--

 

 

Auditors :

 

Name :

Mahendra N. Shah and Company

Chartered Accountants

Address :

E/3, Capital Commercial Centre, Near Sanyas Ashram, Ashram Road, Ahmedabad – 380009, Gujarat, India

PAN.:

AADFM4086H

 

 

CAPITAL STRUCTURE

 

As on 31.03.2012

 

Authorised Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

100000

Equity Shares

Rs.10/- each

Rs.1.000 Million

20000

Preference Shares

Rs.100/- each

Rs.2.000 Millions

 

Total 

 

Rs.3.000 Millions

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

100000

Equity Shares

Rs.10/- each

Rs.1.000 Million

20000

Preference Shares

Rs.100/- each

Rs.2.000 Millions

 

Total 

 

Rs.3.000 Millions

 

Particulars of Share Holders holding more than 5% shares in the Company

Name of Shareholder

No. of Shares held

% of Holding

Mittal H. Mevada

20000

20%

Payal D. Mevada

20000

20

Rukhiben N. Mevada

9500

9.50

Darshan N. Mevada HUF

8000

8.00

Hitesh N. Mevada HUF

8000

8.00

Teeshan D. Mevada

6250

6.25

Prem D. Mevada

6250

6.25

Maan H. Mevada

12500

12.50

 

 


 

FINANCIAL DATA

[all figures are in Rupees Millions]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.03.2012

31.03.2011

31.03.2010

SHAREHOLDERS FUNDS

 

 

 

1] Share Capital

3.000

3.000

3.000

2] Share Application Money

0.000

0.000

0.000

3] Reserves & Surplus

31.628

23.527

10.695

4] (Accumulated Losses)

0.000

0.000

0.000

NETWORTH

34.628

26.527

13.695

LOAN FUNDS

 

 

 

1] Secured Loans

22.290

19.643

21.019

2] Unsecured Loans

2.082

3.950

5.151

TOTAL BORROWING

24.372

23.593

26.170

DEFERRED TAX LIABILITIES

2.697

1.864

0.867

 

 

 

 

TOTAL

61.697

51.984

40.732

 

 

 

 

APPLICATION OF FUNDS

 

 

 

 

 

 

 

FIXED ASSETS [Net Block]

50.601

41.474

29.305

Capital work-in-progress

0.405

0.000

0.000

 

 

 

 

INVESTMENT

14.583

5.017

0.779

DEFERREX TAX ASSETS

0.000

0.000

0.000

 

 

 

 

CURRENT ASSETS, LOANS & ADVANCES

 

 

 

 

Inventories

35.147

29.320

20.265

 

Sundry Debtors

37.101

35.868

34.911

 

Cash & Bank Balances

7.478

0.978

8.738

 

Other Current Assets

0.000

0.000

0.000

 

Loans & Advances

30.252

25.143

16.554

Total Current Assets

109.978

91.309

80.468

Less : CURRENT LIABILITIES & PROVISIONS

 

 

 

 

Sundry Creditors

71.715

53.234

45.093

 

Other Current Liabilities

22.953

16.536

15.508

 

Provisions

19.202

16.046

9.219

Total Current Liabilities

113.870

85.816

69.820

Net Current Assets

(3.892)

5.493

10.648

 

 

 

 

MISCELLANEOUS EXPENSES

0.000

0.000

0.000

 

 

 

 

TOTAL

61.697

51.984

40.732

 


PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

31.03.2012

31.03.2011

31.03.2010

 

SALES

 

 

 

 

 

Revenue from operations

172.158

168.161

138.945

 

 

Other Income

1.548

1.166

2.996

 

 

TOTAL                                     (A)

173.706

169.327

141.941

 

 

 

 

 

Less

EXPENSES

 

 

 

 

 

Cost of materials consumed

98.817

113.315

 

 

 

Changes in inventories

4.930

(9.899)

120.332

 

 

Employee benefit expense

26.639

18.173

 

 

 

Other expenses

23.291

22.499

 

 

 

TOTAL                                     (B)

153.677

144.088

120.332

 

 

 

 

 

Less

PROFIT BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B)      (C)

20.029

25.239

21.609

 

 

 

 

 

Less

FINANCIAL EXPENSES                         (D)

3.560

2.528

3.767

 

 

 

 

 

 

PROFIT BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D)                                       (E)

16.469

22.711

17.842

 

 

 

 

 

Less/ Add

DEPRECIATION/ AMORTISATION                     (F)

2.162

1.221

0.813

 

 

 

 

 

 

PROFIT BEFORE TAX (E-F)                               (G)

14.307

21.490

17.029

 

 

 

 

 

Less

TAX                                                                  (H)

4.904

7.357

7.732

 

 

 

 

 

 

PROFIT AFTER TAX (G-H)                                (I)

9.403

14.133

9.297

 

 

 

 

 

Add

PREVIOUS YEARS’ BALANCE BROUGHT FORWARD

12.525

4.694

1.120

 

 

 

 

 

Less

APPROPRIATIONS

 

 

 

 

 

Transfer to General Reserve

NA

5.000

5.000

 

 

Proposed Dividend Equity Share

NA

1.000

0.500

 

 

Proposed Dividend Preference Share

NA

0.120

0.120

 

 

Tax on Dividend

NA

0.182

0.103

 

BALANCE CARRIED TO THE B/S

NA

12.525

4.694

 

 

 

 

 

 

EARNINGS IN FOREIGN CURRENCY

 

 

 

 

 

Export Earnings

NA

45.401

4.408

 

TOTAL EARNINGS

NA

65.401

4.408

 

 

 

 

 

 

IMPORTS

 

 

 

 

 

Raw Materials

NA

1.724

NA

 

 

Capital Goods

NA

5.174

NA

 

TOTAL IMPORTS

NA

6.898

6.898

 

 

 

 

 

 

Earnings Per Share (Rs.)

94.03

141.33

92.97

 

 

KEY RATIOS

 

PARTICULARS

 

 

31.03.2012

31.03.2011

31.03.2010

PAT / Total Income

(%)

5.41

8.35

6.55

 

 

 

 

 

Net Profit Margin

(PBT/Sales)

(%)

8.24

12.69

12.00

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets}

(%)

8.91

16.18

15.51

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

0.41

0.81

1.24

 

 

 

 

 

Debt Equity Ratio

(Total Liability/Networth)

 

3.99

4.12

7.01

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

0.97

1.06

1.15

 

 

 

LOCAL AGENCY FURTHER INFORMATION

 

Sr. No.

Check List by Info Agents

Available in Report (Yes / No)

1]

Year of Establishment

Yes

2]

Locality of the firm

Yes

3]

Constitutions of the firm

Yes

4]

Premises details

No

5]

Type of Business

Yes

6]

Line of Business

Yes

7]

Promoter's background

Yes

8]

No. of employees

No

9]

Name of person contacted

No

10]

Designation of contact person

No

11]

Turnover of firm for last three years

Yes

12]

Profitability for last three years

Yes

13]

Reasons for variation <> 20%

----------------------

14]

Estimation for coming financial year

No

15]

Capital in the business

Yes

16]

Details of sister concerns

No

17]

Major suppliers

No

18]

Major customers

Yes

19]

Payments terms

No

20]

Export / Import details (if applicable)

No

21]

Market information

----------------------

22]

Litigations that the firm / promoter involved in

----------------------

23]

Banking Details

Yes

24]

Banking facility details

Yes

25]

Conduct of the banking account

----------------------

26]

Buyer visit details

----------------------

27]

Financials, if provided

Yes

28]

Incorporation details, if applicable

Yes

29]

Last accounts filed at ROC

Yes

30]

Major Shareholders, if available

Yes

31]

Date of Birth of Proprietor/Partner/Director, if available

Yes

32]

PAN of Proprietor/Partner/Director, if available

No

33]

Voter ID No of Proprietor/Partner/Director, if available

No

34]

External Agency Rating, if available

No

 

 

PERFORMANCE:

 

The Company has earned revenue from operation of Rs.172.158 Millions as against Rs.168.161 Millions in the previous year resulting a meager improvement of 2.5%. The Company is engaged in the principle business of manufacturing of Pharmaceutical machineries.

 

2011 – 12 started on a high with strong demand pull from the FMCG, Pharma, industries, both in and outside of India. However, as the year progressed, the financial crisis deepened in Europe, the US industry indicators continued to remain weak resulting in an overall slowdown in demand in those economies which finally impacted the finished product price adversely, creating a price-cost imbalance in strategic raw materials.

 

India, the weakening of the rupee put enormous inflationary pressures on the economy in the second half of the current year under review forcing the government to take fiscal measures which stagnated public spending, reduced capital outflow and consumer spending which eventually resulted into weakening of overall market demand for the final products of the Company’s customers. This in turn adversely impacted the Company’s volumes and prices in the second half of the year. As the Company is engaged in providing equipment and pharmaceutical machineries and almost all major pharmaceutical companies have put on hold their Capex Products or are delaying the same and waiting for the economy to turn-around. The forex fluctuations and strengthening of US $ against Indian Rupee has also adversely impacted the exports.

 

The profitability during the year is adversely impacted on account of factors as narrated above and also for the reasons that the Company has substantially invested in strengthening its labour fource, skilled and unskilled man-power, which is a long term strategic measure to meet with the requirements and capture the opportunity whenever there is a positive improvement in the economic conditions.

 

The Company is rigorously pursuing various new markets and expanding its reach to new territories in the global market.

 

The Company has also upgraded its equipments to improve the quality of products to meet with the requirements of quality conscious export market.

 

The Directors are also hopeful of improved performance in the years to come.

 

 

UNSECURED LOAN

Rs. In millions

Particular

As on

31.03.2012

As on

31.03.2011

Long Term Borrowings

 

 

From other Parties :

 

 

Directors

0.254

0.237

Share Holders

1.828

3.713

Total

2.082

3.950

 

 

FIXED ASSETS

 

·         Buildings

·         Plant and Equipment

·         Furniture and Fixtures

·         Vehicles

·         Other Equipment

 

 


CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                              None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                          None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                          None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 


 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.54.64

UK Pound

1

Rs.87.46

Euro

1

Rs.72.65

 

 

INFORMATION DETAILS

 

Report Prepared by :

NTH

 


 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

5

PAID-UP CAPITAL

1~10

5

OPERATING SCALE

1~10

5

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

5

--PROFITABILIRY

1~10

5

--LIQUIDITY

1~10

5

--LEVERAGE

1~10

5

--RESERVES

1~10

5

--CREDIT LINES

1~10

5

--MARGINS

-5~5

--

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

NO

--AFFILIATION

YES/NO

NO

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

TOTAL

 

45

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

-

NB

                                       New Business

-

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.